Orchestra BioMed (OBIO) Expected to Announce Quarterly Earnings on Monday

Key Points

• Orchestra BioMed is expected to report Q3 2026 results on November 9, with analysts forecasting a loss of $0.40 per share and revenue of approximately $0.13 million. The earnings call is scheduled for November 10 at 4:00 p.m. ET.
• In the prior quarter, the company reported a $0.38-per-share loss, slightly better than estimates, but revenue of $0.09 million fell short of expectations. Analysts project full-year and next-year losses of $1.53 and $1.45 per share, respectively.
• Wall Street maintains a generally positive view, with six Buy ratings and one Sell rating and an average price target of $13.17 versus the recent $5.91 share price. Orchestra BioMed’s stock has traded between $3.46 and $6.50 over the past year, while insiders own 7.5% of the company.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) will likely be releasing its Q3 2026 resultson Monday, November 9th. Analysts expect Orchestra BioMed to announce earnings of ($0.40) per share and revenue of $0.13 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.01. Orchestra BioMed had a negative return on equity of 149.61% and a negative net margin of 184.60%. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.14 million. On average, analysts expect Orchestra BioMed to post ($1.53) EPS for the current fiscal year and ($1.45) EPS for the next fiscal year.

Orchestra BioMed Price Performance

OBIO opened at $5.91 on Monday. The company has a debt-to-equity ratio of 1.80, a current ratio of 8.26 and a quick ratio of 8.24. The stock's 50 day simple moving average is $5.70 and its 200 day simple moving average is $4.54. The firm has a market cap of $355.19 million, a price-to-earnings ratio of -6.95 and a beta of 0.56. Orchestra BioMed has a 1 year low of $3.46 and a 1 year high of $6.50.

Wall Street Analysts Forecast Growth

OBIO has been the topic of several analyst reports. Piper Sandler reaffirmed an "overweight" rating on shares of Orchestra BioMed in a research note on Thursday, October 15th. Weiss Ratings raised shares of Orchestra BioMed from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 10th. B. Riley Financial raised their price target on shares of Orchestra BioMed from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Orchestra BioMed in a research report on Monday, October 5th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $20.00 price objective on shares of Orchestra BioMed in a research note on Friday, October 23rd. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $13.17.

Insider Activity

In related news, insider David P. Hochman acquired 10,000 shares of the stock in a transaction on Thursday, September 3rd. The stock was acquired at an average cost of $4.79 per share, for a total transaction of $47,900.00. Following the completion of the acquisition, the insider directly owned 1,070,746 shares of the company's stock, valued at approximately $5,128,873.34. This represents a 0.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Darren Sherman sold 15,000 shares of Orchestra BioMed stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $6.36, for a total value of $95,400.00. Following the sale, the insider directly owned 1,119,402 shares in the company, valued at approximately $7,119,396.72. The trade was a 1.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.50% of the company's stock.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization.

Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.